CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net income	$ 5,415	$ 48,893
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	33,648	31,237
Amortization of debt discount and issuance costs	7,727	914
Stock-based compensation	17,990	12,737
Deferred income taxes, net	(2,634)	(2,196)
Contingent consideration	0	3,026
Non-cash interest income	0	(2,023)
Other	(172)	574
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(1,245)	(4,606)
Inventories	10,474	(2,508)
Prepaid expenses and other assets	(1,999)	(11,530)
Operating lease right of use assets	(16,349)	6,487
Other assets	364	(888)
Accounts payable	1,547	(3,871)
Accrued expenses	8,366	(26,234)
Operating lease Liabilities	23,867	(4,544)
Long-term liabilities	(101)	154
Total cash provided by operating activities	86,898	45,622
Cash flows from investing activities:
Acquisitions, net of cash acquired	0	(28,099)
Proceeds from maturity of marketable securities held to maturity	0	102,323
Additions to capitalized software costs	(2,619)	(2,075)
Purchases of property, plant and equipment	(13,154)	(16,749)
Other investing activities	11	0
Total cash (used in) provided by investing activities	(15,762)	55,400
Cash flows from financing activities:
Proceeds from exercise of stock options	1,788	62
Payment of tax withholding obligation on vesting of restricted stock	(8,857)	(11,140)
Payment of earnout consideration	(7,375)	(7,298)
Other financing activities	(303)	(12)
Total cash used in financing activities	(14,747)	(18,388)
Effect of exchange rate changes on cash and cash equivalents	1,434	(2,436)
Net increase in cash and cash equivalents	57,823	80,198
Cash, cash equivalents, beginning of period	751,323	523,458
Cash and cash equivalents, end of period	809,146	603,656
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	23,860	831
Fair value of shares of common stock issued for contingent consideration earnouts	5,742	7,229
FlexBiosys, Inc.
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition	$ 0	$ 5,243